Navigation Links
Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
Date:10/14/2010

SEATTLE, Oct. 14 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER) today announced that the National Institute on Drug Abuse (NIDA) has provided an additional grant to fund clinical studies for the Company's Addiction program. This grant, which is for a total of approximately $3.6 million to be paid over a four-year period in equal amounts, will fund direct and indirect costs of Phase 2 clinical studies to be conducted by researchers at the New York State Psychiatric Institute (NYSPI). In Omeros' Addiction program, the Company is developing proprietary compositions that include peroxisome proliferator-activated receptor gamma (PPARgamma) agonists for the prevention and treatment of addiction to substances of abuse, such as opioids, nicotine and alcohol, as well as other compulsive behaviors, including eating disorders. Data from earlier European pilot clinical studies and animal models of addiction have demonstrated a previously unknown link between PPARgamma and addiction disorders.

Earlier this year, Omeros announced that NIDA agreed to fund substantially all of the costs of a Phase 2 clinical study to be conducted by NYSPI researchers to evaluate a PPARgamma agonist for the treatment of addiction to prescription opioids. The NIDA support announced today will be used to fund additional Phase 2 clinical studies to evaluate the effect of a PPARgamma agonist in combination with other agents on the use of heroin and cigarettes.  These clinical studies will also be conducted at the NYSPI and will be led by the recipients of this grant award, Dr. Sandra D. Comer and Dr. Adam Bisaga. Omeros will have the right to reference the data obtained from these studies for subsequent submissions to the FDA and will retain all other rights in connection with its Addiction program.

"This latest grant from NIDA underscores the potential of our Addiction program to yield a
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Omeros Secures $40 Million Committed Equity Financing Facility
2. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
3. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
4. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
5. Omeros Commences Initial Public Offering of Common Stock
6. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
7. Omeros Appoints New Vice President of Clinical Development
8. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
9. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
10. Omeros and BlueCrest Announce $20 Million Debt Facility
11. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Topical BioMedics, Inc., is ... pain end their suffering, restoring hope an quality of ... is only possible because of the innovative cellular biomedicines ... technology a reality. , The company was founded ... Lou Paradise (president, chief of research, and Topricin inventor), ...
(Date:9/22/2014)... Sept. 22, 2014 Research and Markets ... and Chinese Microcrystalline Cellulose Industry Report 2014" report ... Chinese Microcrystalline Cellulose Industry Report 2014 is a professional ... global microcrystalline cellulose industry with a focus on the ... overview of the industry including definitions, classifications, applications and ...
(Date:9/22/2014)... -- Neogen Corporation (Nasdaq: NEOG ) announced today ... 2015 fiscal year, which ended Aug. 31, was $8,883,000 ... $7,839,000 in the first quarter of last year. Adjusted ... earnings per share in the current quarter were $0.24, ... quarter revenues increased 15% to $67,599,000, from the previous ...
(Date:9/22/2014)... LONDON , September 22, 2014 ... ended on a mixed note as the Dow Jones ... NASDAQ Composite closed at 4,579.79, down 0.30%. The S&P ... the trading session, six out of ten sectors finished ... Sector Index ended the day at 751.48, up 0.10%, ...
Breaking Biology Technology:Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5
... Submission Seeks Approval of Genasense in Relapsed/Refractory Patients, ... (Nasdaq: GNTA ) announced that the Company ... to Dr. Janet Woodcock, Acting,Director of the Center ... and Drug Administration (FDA). The appeal asks that ...
... FRANCISCO, Calif., Oct. 25 Cell,Genesys, Inc. (Nasdaq: ... and chief executive officer, and Sharon E. Tetlow, senior,vice ... host a,conference call relating to the company,s third quarter ... on Thursday, November 1,2007, at 2:00 p.m. PT/ 5:00 ...
... will Include World-Renowned RNase and RNA Researchers, ... mechanics of ribonuclease (RNase) therapeutics will be the ... hosted by Alfacell,Corporation (Nasdaq: ACEL ). ... chief,executive officer, and David Sidransky, M.D., Alfacell,s scientific,advisory ...
Cached Biology Technology:Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 2Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 3Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 4Genta Completes Appeal of FDA Decision for Genasense(R) in CLL 5Cell Genesys to Webcast Third Quarter 2007 Conference Call 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 2Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 3Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29 4
(Date:9/19/2014)... of dinosaurs a newly discovered hadrosaur with ... named Rhinorex condrupus by paleontologists from ... lived in what is now Utah approximately 75 ... , Rhinorex, which translates roughly into "King Nose," ... other Cretaceous hadrosaurs like Parasaurolophus and Edmontosaurus. Hadrosaurs ...
(Date:9/19/2014)... will study the unique bioelectric signaling system of the ... health. The OU researcher is working to understand ... the signals used to map the world around them. ... of 500-600 discharges a second throughout their lives. ... extreme, but necessary for survival. , "There is evidence ...
(Date:9/19/2014)... sense of fairness did not evolve for the sake ... the benefits of continued cooperation, so say Frans de ... review article about inequity aversion (IA), which is defined ... is published in Science . , Their ... IA-related studies to address their hypothesis that it is ...
Breaking Biology News(10 mins):New hadrosaur noses into spotlight 2Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3
... Indians of Panama, an international team of scientists ... part, responsible, for the heart-healthy benefits of certain ... who are from the University of California, Davis; ... Medical School, hope the findings will lead to ...
... "fingerprinting" techniques, two University of Minnesota researchers have become ... plants with genetic markers. , Hemp, a crop ... the most abundant illegal drug of abuse in the ... They differ in levels of the psychoactive drug tetrahydrocannabinol ...
... used for genetics-versus-environment studies has joined the panoply of ... genomes have been sequenced. , At the Daphnia Genomics ... and Joint Genome Institute scientists announced they've completed a ... as it's better known to high school biology students. ...
Cached Biology News:Heart-healthy compound in chocolate identified 2New DNA 'fingerprinting' technique separates hemp from marijuana 2Genome sequencing is for ecologists, too 2
...
Candida (IgG) -Ab EIA Sample Size: 5 l...
Automated centrifuge for the processing of microplates and tubes; can be integrated into automated process using inexpensive robotics due to its unique sample handling platform....
OptiBuffer is a fully optimised medium, designed for,the electroporation of eukaryotic cells. OptiBuffer,improves both transfection efficiencies and survival,rates over PBS or other standard culture...
Biology Products: